Skip to content

Medical Reference Related to Prostate Cancer

  1. Prostate Cancer, Nutrition, and Dietary Supplements (PDQ®): Complementary and alternative medicine - Patient Information [NCI] - About This PDQ Summary

    About PDQPhysician Data Query (PDQ) is the National Cancer Institute's (NCI's) comprehensive cancer information database. The PDQ database contains summaries of the latest published information on cancer prevention, detection, genetics, treatment, supportive care, and complementary and alternative medicine. Most summaries come in two versions. The health professional versions have detailed information written in technical language. The patient versions are written in easy-to-understand, nontechnical language. Both versions have cancer information that is accurate and up to date and most versions are also available in Spanish.PDQ is a service of the NCI. The NCI is part of the National Institutes of Health (NIH). NIH is the federal government's center of biomedical research. The PDQ summaries are based on an independent review of the medical literature. They are not policy statements of the NCI or the NIH.Purpose of This SummaryThis PDQ cancer information summary has current

  2. Prostate Cancer Treatment (PDQ®): Treatment - Health Professional Information [NCI] - nci_ncicdr0000062910-nci-header

    This information is produced and provided by the National Cancer Institute (NCI). The information in this topic may have changed since it was written. For the most current information, contact the National Cancer Institute via the Internet web site at http://cancer.gov or call 1-800-4-CANCER.Prostate Cancer Treatment

  3. Stage II Prostate Cancer Treatment

    OverviewStage II prostate cancer is defined by the American Joint Committee on Cancer's TNM classification system:[1]Stage IIAT1a–c, N0, M0, prostate-specific antigen (PSA) <20 ng/ml, Gleason 7.T1a–c, N0, M0, PSA ≥10 <20 ng/ml, Gleason ≤6.T2a, N0, M0, PSA ≥10 <20 ng/ml, Gleason ≤6.T2a, N0, M0, PSA <20 ng/ml, Gleason 7.T2b, N0, M0, PSA <20 ng/ml, Gleason ≤7.T2b, N0, M0, PSA X, Gleason X.Stage IIBT2c, N0, M0, any PSA, any Gleason.T1–2, N0, M0, PSA ≥20 ng/ml, any Gleason.T1–2, N0, M0, any PSA, Gleason ≥8.Radical prostatectomy, external-beam radiation therapy (EBRT), and interstitial implantation of radioisotopes are each employed in the treatment of stage II prostate cancer with apparently similar therapeutic effects. Radical prostatectomy and radiation therapy yield apparently similar survival rates with as many as 10 years of follow-up. For well-selected patients, radical prostatectomy

  4. Prostate Cancer, Nutrition, and Dietary Supplements (PDQ®): Complementary and alternative medicine - Health Professional Information [NCI] - Zyflamend

    OverviewZyflamend is a dietary supplement that contains extracts of rosemary, turmeric, ginger, holy basil, green tea, hu zhang, Chinese goldthread, barberry, oregano, and Baikal skullcap.The individual components of Zyflamend have anti-inflammatory and possible anticarcinogenic properties.In various preclinical studies, Zyflamend has been shown to suppress the expression of certain genes involved in the inflammatory response and in cancer progression, such as cyclooxygenase 1(COX-1), COX-2, 5-lipoxygenase (5-LOX), and 12-LOX.In other preclinical studies, Zyflamend has demonstrated single-agent anticancer activity, and the capacity to be combined with hormonal and chemotherapy agents for improved cancer suppression.Results of a phase I study of Zyflamend suggest that use of this supplement is not associated with serious toxicity or adverse effects.General Information and HistoryZyflamend is a dietary supplement that contains extracts of rosemary, turmeric, ginger, holy

  5. Genetics of Prostate Cancer (PDQ®): Genetics - Health Professional Information [NCI] - Introduction

    Many of the medical and scientific terms used in this summary are found in the NCI Dictionary of Genetics Terms. When a linked term is clicked,the definition will appear in a separate window. The public health burden of prostate cancer is substantial. A total of 186,320 new cases of prostate cancer and 28,660 deaths from the disease are anticipated in the United States in 2008,making it the ...

  6. Prostate Cancer Prevention (PDQ®): Prevention - Patient Information [NCI] - What is prevention?

    WebMD discusses methods of preventing prostate cancer.

  7. Recurrent Prostate Cancer Treatment

    OverviewIn recurrent prostate cancer, the selection of further treatment depends on many factors, including:Previous treatment.Site of recurrence.Coexistent illnesses.Individual patient considerations. Definitive radiation therapy can be given to patients with disease that fails only locally following prostatectomy.[1,2,3,4] An occasional patient can be salvaged with prostatectomy after a local recurrence following definitive radiation therapy;[5] however, only about 10% of patients treated initially with radiation therapy will have local relapse only. In these patients, prolonged disease control is often possible with hormonal therapy, with median cancer-specific survival of 6 years after local failure.[6]Cryosurgical ablation of recurrence following radiation therapy is associated frequently with a high complication rate. This technique is still undergoing clinical evaluation.[7]Hormonal therapy is used to manage most relapsing patients with

  8. Genetics of Prostate Cancer (PDQ®): Genetics - Health Professional Information [NCI] - Identifying Genes and Inherited Variants Associated with Prostate Cancer Risk

    Various research methods have been employed to uncover the landscape of genetic variation associated with prostate cancer. Specific methodologies inform of unique phenotypes or inheritance patterns. The sections below describe prostate cancer research utilizing various methods to highlight their role in uncovering the genetic basis of prostate cancer. In an effort to identify disease susceptibility genes, linkage studies are typically performed on high-risk extended families in which multiple cases of a particular disease have occurred. Typically, gene mutations identified through linkage analyses are rare in the population, highly penetrant in families, and have large effect sizes. The

  9. Prostate Cancer Treatment (PDQ®): Treatment - Patient Information [NCI] - Recurrent Prostate Cancer

    Recurrent prostate cancer is cancer that has recurred (come back) after it has been treated. The cancer may come back in the prostate or in other parts of the body.

  10. Prostate Cancer Treatment (PDQ®): Treatment - Patient Information [NCI] - General Information About Prostate Cancer

    Prostate cancer is a disease in which malignant (cancer) cells form in the tissues of the prostate. The prostate is a gland in the male reproductive system located just below the bladder (the organ that collects and empties urine) and in front of the rectum (the lower part of the intestine). It is about the size of a walnut and surrounds part of the urethra (the tube that empties urine from the

Displaying 11 - 20 of 258 Articles << Prev Page 1 2 3 4 5 6 7 8 9 10 Next >>

Today on WebMD

man with doctor
Symptoms, risks, treatments
man coughing
Men shouldn’t ignore
 
prostate cancer cells
What does this diagnosis mean?
doctor and male patient
Is it worth it?
 
cancer fighting foods
SLIDESHOW
15 Cancer Symptoms Men Ignore
FEATURE
 
Prostate Enlarged
VIDEO
Picture Of The Prostate
ANATOMY
 
Prostate Cancer Quiz
QUIZ
screening tests for men
SLIDESHOW
 
Prostate Cancer Symptoms
VIDEO
Vitamin D
SLIDESHOW